Skip to main content

Spero Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 13, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 13, 2024

SPRO$1.07+3.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. Form 10-K Summary

None.

SIGNAT URES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SPERO THERAPEUTICS, INC.
Date: March 13, 2024By:/s/ Satyavrat Shukla
Satyavrat Shukla
President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Satyavrat Shukla and Esther Rajavelu his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, each of the undersigned has executed this Power of Attorney as of the date indicated opposite his or her name.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

NameTitleDate
/s/ Satyavrat ShuklaPresident, Chief Executive Officer and DirectorMarch 13, 2024
Satyavrat Shukla(Principal Executive Officer)
/s/ Esther RajaveluChief Financial Officer, Chief Business Officer and TreasurerMarch 13, 2024
Esther Rajavelu(Principal Financial Officer and Principal Accounting Officer)
/s/ Milind Deshpande, Ph.D.DirectorMarch 13, 2024
Milind Deshpande, Ph.D.
/s/ Scott JacksonDirectorMarch 13, 2024
Scott Jackson
/s/ Ankit Mahadevia, M.D.ChairmanMarch 13, 2024
Ankit Mahadevia, M.D.
/s/ John C. Pottage, M.D.DirectorMarch 13, 2024
John C. Pottage, M.D.
/s/ Cynthia SmithDirectorMarch 13, 2024
Cynthia Smith
/s/ Frank E. ThomasDirectorMarch 13, 2024
Frank E. Thomas
/s/ Kathleen TregoningDirectorMarch 13, 2024
Kathleen Tregoning
/s/ Patrick Vink, M.D.DirectorMarch 13, 2024
Patrick Vink, M.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.